FREQUENCY OF THYROID DYSFUNCTION IN CASES OF METABOLIC SYNDROME PRESENTING AT TERTIARY CARE HOSPITAL

NU HUDA; UA ALI; W ABBASI

doi:10.54112/bcsrj.v2024i1.896

Authors

NU HUDA Department of Medicine, Ayub Teaching Hospital Abbottabad, Pakistan
UA ALI Department of Medicine, Ayub Teaching Hospital Abbottabad, Pakistan
W ABBASI Department of Medicine, Ayub Teaching Hospital Abbottabad, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.896

Keywords:

Metabolic Syndrome, Thyroid Dysfunction, Subclinical Hypothyroidism

Abstract

Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes. Thyroid dysfunction is frequently observed in patients with metabolic syndrome, impacting their overall health outcomes. Objective: To determine the frequency of thyroid dysfunction in patients with metabolic syndrome. Methods: This cross-sectional study was conducted at the Department of Medicine, Ayub Teaching Hospital, Abbottabad, from September 2023 to March 2024. A total of 120 patients diagnosed with metabolic syndrome were included. The patients' thyroid function was assessed through clinical evaluation and laboratory tests, including serum levels of TSH, free T3, and free T4. Statistical analysis was performed using descriptive statistics to determine the frequency of thyroid dysfunction, with results expressed as percentages and means ± standard deviations. Results: The average age of the 120 patients was 44.64±9.01 years. The frequency of thyroid dysfunction among these patients was 68.4% (82/120). Subclinical hypothyroidism was present in 27.5% (33/120), hypothyroidism in 14.2% (17/120), and subclinical hyperthyroidism in 4.2% (5/120). Conclusion: The study found a high frequency of thyroid dysfunction (68.4%) in patients with metabolic syndrome, with subclinical hypothyroidism being the most prevalent form. These findings highlight the importance of regular thyroid function screening in patients with metabolic syndrome to ensure early diagnosis and management.

Downloads

Download data is not yet available.

References

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640-5.

SAMSON K. PD Patients' Skin Cells Reprogrammed Into Stem Cells for Dopamine: New Technique Removes Oncogenic Genes Afterwards. Neurology Today. 2009;9(8):1-23.

Nilsson PM, Tuomilehto J, Rydén L. The metabolic syndrome–What is it and how should it be managed? European journal of preventive cardiology. 2019;26(2_suppl):33-46.

Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. Sex-and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacological research. 2017;120:34-42.

Caballero B. Humans against obesity: who will win? Advances in nutrition. 2019;10:S4-S9.

Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. The Journal of clinical investigation. 2017;127(1):1-4.

Lemieux I, Després J-P. Metabolic syndrome: past, present and future. MDPI; 2020. p. 3501.

Chakradhar M, Chakravarthy D, Bhaskar DS, Kiran DM, Bhavani NP. Thyroid Dysfunction in Metabolic Syndrome Patients in a Tertiary Care Hospital. Journal of Evolution of Medical and Dental Sciences. 2020;9(30):2103-9.

Zhu Q, Jiang G, Lang X, Zhang J, Fu Z, Zhang P, et al. Prevalence and clinical correlates of thyroid dysfunction in first-episode and drug-naïve major depressive disorder patients with metabolic syndrome. Journal of affective disorders. 2023;341:35-41.

Cappola AR, Desai AS, Medici M, Cooper LS, Egan D, Sopko G, et al. Thyroid and cardiovascular disease: research agenda for enhancing knowledge, prevention, and treatment. Circulation. 2019;139(25):2892-909.

Gluvic ZM, Zafirovic SS, Obradovic MM, Sudar-Milovanovic EM, Rizzo M, Isenovic ER. Hypothyroidism and risk of cardiovascular disease. Current Pharmaceutical Design. 2022;28(25):2065-72.

Mehran L, Amouzegar A, Azizi F. Thyroid disease and the metabolic syndrome. Current Opinion in Endocrinology, Diabetes and Obesity. 2019;26(5):256-65.

Kota SK, Meher LK, Krishna S, Modi K. Hypothyroidism in metabolic syndrome. Indian journal of endocrinology and metabolism. 2012;16(Suppl 2):S332-S3.

Azizi F, Amouzegar A, Delshad H, Tohidi M, Mehran L, Mehrabi Y. Natural course of thyroid disease profile in a population in nutrition transition: Tehran Thyroid Study. Archives of Iranian medicine. 2013;16(7):0-.

Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10:1-15.

Amouzegar A, Delshad H, Mehran L, Tohidi M, Khafaji F, Azizi F. Reference limit of thyrotropin (TSH) and free thyroxine (FT 4) in thyroperoxidase positive and negative subjects: a population based study. Journal of endocrinological investigation. 2013;36:950-4.

AZIZI F, Khalili D, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, et al. Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity. 2010.

Gyawali P, Takanche JS, Shrestha RK, Bhattarai P, Khanal K, Risal P, et al. Pattern of thyroid dysfunction in patients with metabolic syndrome and its relationship with components of metabolic syndrome. Diabetes & metabolism journal. 2015;39(1):66.

Khatiwada S, Sah SK, Kc R, Baral N, Lamsal M. Thyroid dysfunction in metabolic syndrome patients and its relationship with components of metabolic syndrome. Clinical Diabetes and Endocrinology. 2016;2:1-5.